Amgen Gains Worldwide Rights to Biovitrum's Lead Candidate For Type 2 Diabetes

Filed in archive Corporate and Industrial News , Drugs, Vaccines and Therapeutics , Patents and Intellectual Property Rights by ruth on February 14, 2006

In a revised, expanded agreement, Amgen receives exclusive worldwide rights to develop and commercialize Biovitrum's drug candidate for Type 2 diabetes and related metabolic Diseases. Previously, Amgen had exclusive rights to commercialize products only in North and South America, the European Union, Australia and New Zealand.

Biovitrum's lead compound, 11beta-HSD1 enzyme inhibitors, are currently under early clinical development.

Related Entries:

Amgen Acquires Abgenix for $2.2 B - 15 December 2005
Top 20 Molecular Millionaires - 31 May 2006
Obesity Leads to Type 2 Diabetes - 05 February 2007
Amgen Buys Ilypsa for $420 Million - 06 June 2007
Novo Nordisk's Levemir®, Approved in Japan - 23 October 2007
'Laziness' of Regulatory T-cells, Lead to Type 1 Diabetes - 18 January 2008
Diet and Type 2 Diabetes - 15 July 2008

« Ribomed Biotech Granted $... | Main | First Commercial Plant Fo... »

Permalink: Amgen Gains Worldwide Rights to Biovitrum's Lead Candidate For Type 2 Diabetes

Tags: diabetes amgen biotech type rights type+diabetes biovitrum+lead candidate+type

Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/15480

Addthis

Ask

Blinklist

del.icio.us

Digg

Fark

Facebook

Google

Lycos

Ma.gnolia

Mr Wong

Netscape

Netvousz

Newsvine

StumbleUpon

Slashdot

Tailrank

Technorati

Wink

Yahoo

Vote for Amgen Gains Worldwide Rights to Biovitrum's Lead Candidate For Type 2 Diabetes:

Currently 6.00/10
1
2
3
4
5
6
7
8
9
10

Rating: 6.00 out of 1 vote(s) cast.

Response from: James Hatton (02/16/06 3:26pm)

So when they expanded the collaboration, I wonder what the "rest of the world" was worth?

When they signed the 2003 license (the winner of the "Best of Biotech 2004" award for "Most Creative and Significant Deal"), the September 8, 2003 press release disclosed that the license fee was $87 million.

Add your response to Amgen Gains Worldwide Rights to Biovitrum's Lead Candidate For Type 2 Diabetes:

Name: *

Email: (will never be shown)*

URL:

(* marked fields are required)

Notify me if more comments appear?

Subscribe to The Biotech Weblog newsletter? (Newsletters are sent out weekly).

Remember me

Security Code: *
(Please help us to sort out spam.)

Please enter your comment here: (Sorry, no HTML is allowed - URLs will be made clickable automatically if you add http:// to your URL.)

We welcome your comments, however all comments are moderated. Offensive or off-topic comments will be deleted and not displayed.

Share It

Use the search to look for other interesting posts

Contributors (Last 90 days)

Shawn Hessinger (1)
Gloria Gamat (5)
Ruth Schaffer (14)
Creative Weblogging (3)

This site has 1333 entries and is powered by Creative Weblogging since July 2005.

Our Editors recommend

Disclaimer

Some of the contents of this site are protected Creative Weblogging Inc. 2004-2010.

Check out our Sponsored Blogs!

Business Computer Blog (UK)

Are you interested in writing a blog in our network?

See which positions are currently open.

Testimonials

'Very nice blog layout with great content. Are you interested in Star Trek props that are quickly becoming reality? Then this is the blog for you. Human medical scanners, nano technology and more great technological advancements.' -VirtualLoop Blog of the Week

'I subscribe to your blog and have been enjoying your posts and perspective.'

Other blogs in the same channel in the Creative Weblogging Network: Health & Life Sciences

RSS	See all blog subscribe options
Google	What is RSS?
Yahoo!
Addthis
Bloglines
Newsletter
Twitter	Follow us on Twitter!